Wedmont Private Capital Acquires 384 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wedmont Private Capital raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,633 shares of the pharmaceutical company’s stock after buying an additional 384 shares during the period. Wedmont Private Capital’s holdings in Vertex Pharmaceuticals were worth $1,488,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Northwest Investment Counselors LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $25,000. Dunhill Financial LLC boosted its position in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $27,000. GHP Investment Advisors Inc. bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $29,000. Finally, Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $413.37 on Tuesday. The stock’s fifty day moving average price is $447.69 and its 200 day moving average price is $467.53. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The company has a market cap of $106.45 billion, a price-to-earnings ratio of -207.72 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $3.67 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on VRTX shares. JPMorgan Chase & Co. lowered their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, December 23rd. Barclays dropped their price target on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Finally, BMO Capital Markets reduced their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.